

***Amendments to the Specification***

Please replace the paragraph beginning at page 1, line 8 with the following amended paragraphs:

This application is a continuation-in-part (CIP) of Application No. 09/098,584, filed June 17, 1998, abandoned, which is herein incorporated by reference; and is a CIP of International Application No. PCT/US99/13789, filed June 17, 1999, which published under PCT Article 21(2) in English; and is a CIP of Application No. 09/017,735, filed February 3, 1998, which is herein incorporated by reference, which is a CIP of Application No. 08/589,108, filed January 23, 1996, abandoned, which is herein incorporated by reference; and is a CIP of Application No. 09/016,361, filed January 30, 1998, abandoned.

This application is also related to a Continuation-In-Part ("CIP") of U.S.S.N. 09/189,702, filed 11/10/98, which is a CIP of U.S.S.N. 08/205,713 filed 3/4/94, which is a CIP of abandoned U.S.S.N. 08/159,184 filed 11/29/93, which is a CIP of abandoned U.S.S.N. 08/073,205 filed 6/4/93 which is a CIP of abandoned U.S.S.N. 08/027,146 filed 3/5/93. The present application is also related to U.S.S.N. 09/226,775, which is a CIP of abandoned U.S.S.N. 08/815,396, which claims benefit of abandoned U.S.S.N. 60/013,113. Furthermore, the present application is related to ~~U.S.S.N. 09/017,735, which is a CIP of abandoned U.S.S.N. 08/589,108;~~ U.S.S.N. 08/454,033; and U.S.S.N. 08/349,177. The present application is also related to U.S.S.N. 09/017,524, U.S.S.N. 08/821,739, which claims benefit of abandoned U.S.S.N. 60/013,833; and U.S.S.N. 08/347,610, which is a CIP of U.S.S.N. 08/159,339, which is a CIP of abandoned U.S.S.N. 08/103,396, which is a CIP of abandoned U.S.S.N. 08/027,746, which is a CIP

of abandoned U.S.S.N. 07/926,666. The present application is also related to U.S.S.N. 09/017,743, which is a CIP of abandoned U.S.S.N. 08/590,298; and U.S.S.N. 08/452,843, which is a CIP of U.S.S.N. 08/344,824, which is a CIP of abandoned U.S.S.N. 08/278,634. The present application is also related to PCT application 99/12066 filed 5/28/99 which claims benefit of provisional U.S.S.N. 60/087,192, and U.S.S.N. 09/009,953, which is a CIP of abandoned U.S.S.N. 60/036,713 and abandoned U.S.S.N. 60/037,432. In addition, the present application is related to ~~U.S.S.N. 09/098,584~~, U.S.S.N. 09/239,043, U.S.S.N. 60/117,486, U.S.S.N. 09/350,401, and U.S.S.N. 09/357,737. In addition, the present application is related to U.S.S.N. 09/458,297, filed December 10, 1999; U.S.S.N. 09/458,298, filed December 10, 1999; U.S.S.N. 09/458,299, filed December 10, 1999. U.S. Patent Application entitled "Inducing Cellular Immune Responses to p53 Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014500, filed of even date herewith; U.S. Patent Application entitled "Inducing Cellular Immune Responses to MAGE2/3 Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014600, filed of even date herewith; and U.S. Patent Application entitled "Inducing Cellular Immune Responses to HER2/neu Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014800, filed of even date herewith. All of the above applications in this paragraph are incorporated herein by reference.

Please replace the paragraph beginning at page 12, line 25 with the following amended paragraph:

The term "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the  $\alpha$ -amino and carboxyl groups of adjacent amino acids. The preferred CTL-inducing peptides of the invention are less than about 15 residues in length or 13 residues or less in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues. The preferred HTL-inducing oligopeptides are less than about 50 residues in length and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25, and often between about 15 and 20 residues.

Please insert the Substitute Sequence Listing submitted herewith at the end of the application in place of the previously submitted sequence listing.